<?xml version="1.0" encoding="UTF-8"?>
<p id="Par59">A potential shortcoming of the current trial is the heterogeneous patient population having different causes of thrombocytopenia. Our study includes the two patient populations in which thrombocytopenia and central venous cannulisation are most frequent. We believe that this is also is a strength of our study, allowing results to be extrapolated to various patients categories.</p>
